ACRS Aclaris Therapeutics
- 1.310
- -0.050-3.68%
- 1.300
- -0.010-0.76%
Aclaris Therapeutics News
Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks
HW Wainwright Cuts Aclaris to Neutral, Cites Underwhelming Study Data
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics (ACRS) Was Downgraded to a Hold Rating at BTIG
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aclaris Therapeutics (ACRS) and Quanterix (QTRX)
Aclaris Therapeutics Analyst Ratings
Aclaris Downgraded at Jefferies Despite Mid-stage Win for Eczema Therapy
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)
Aclaris Therapeutics Analyst Ratings
Buy Rating Justified by Aclaris Therapeutics' Strategic Focus and Robust Financial Management
Stifel Nicolaus Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)
Stifel Maintains Hold on Aclaris Therapeutics, Lowers Price Target to $1
Aclaris Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $9
The Latest Analyst Ratings for Aclaris Therapeutics
Hold Rating on Aclaris Therapeutics: Unfavorable ATI-450 Trial Results and Uncertainty on Upcoming ATI-1777 Trial
Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS), Aclaris Therapeutics (ACRS) and CryoPort (CYRX)
Evercore ISI Cuts Aclaris Therapeutics' Price Target to $3 From $22, Keeps Outperform Rating
Analysis
Price Target
No Data
